|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2006-8-31
|
|
pubmed:abstractText |
Trastuzumab-based chemotherapy can improve median survival in the metastatic setting when used in patients with cancer that overexpresses HER2/neu. In addition to HER2 expression, other molecular markers are needed to better predict outcomes after the initiation of trastuzumab-based chemotherapy and to elucidate potential mechanisms of resistance to trastuzumab.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/trastuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1526-8209
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
7
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
254-61
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16942643-Antibodies, Monoclonal,
pubmed-meshheading:16942643-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:16942643-Antineoplastic Agents,
pubmed-meshheading:16942643-Breast Neoplasms,
pubmed-meshheading:16942643-British Columbia,
pubmed-meshheading:16942643-Databases, Factual,
pubmed-meshheading:16942643-Disease-Free Survival,
pubmed-meshheading:16942643-Female,
pubmed-meshheading:16942643-Humans,
pubmed-meshheading:16942643-Immunohistochemistry,
pubmed-meshheading:16942643-Medical Records,
pubmed-meshheading:16942643-Microarray Analysis,
pubmed-meshheading:16942643-Neoplasm Metastasis,
pubmed-meshheading:16942643-Predictive Value of Tests,
pubmed-meshheading:16942643-Receptor, erbB-2,
pubmed-meshheading:16942643-Retrospective Studies,
pubmed-meshheading:16942643-Survival Analysis,
pubmed-meshheading:16942643-Tumor Markers, Biological
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Molecular predictive factors in patients receiving trastuzumab-based chemotherapy for metastatic disease.
|
|
pubmed:affiliation |
Division of Medical Oncology , BC Cancer Agency, Canada. arobinson@hrsrh.on.ca
|
|
pubmed:publicationType |
Journal Article,
Evaluation Studies
|
